Dear Investor,

I am excited and optimistic about the direction EnWave will take in the coming months, based on some key milestones already reached in the first quarter of 2008.

As I look to the rest of 2008 and beyond, I am encouraged by EnWave’s strong growth potential. I believe this will be a key year for the company with our focus on selling the first commercial scale nutraREV technology, and proving the process feasibility of our bioREV and powderREV platforms.

Keep reading for industry news and more detail on EnWave’s accomplishments this Spring. I hope you enjoy our new newsletter format, and encourage you to use the link at the bottom of this email to forward it along to your colleagues and friends.

Sincerely,
John McNicol
President & Co-CEO
EnWave Corporation

In February 2008, EnWave partnered with British Columbia blueberry producer CAL-SAN Enterprises to test the continuous nutraREV process.

We’re excited to be starting the testing phase and are beginning with the machine’s ability to dehydrate berries in small quantities to establish acceptable quality standards.

> Read more

In March, Aridis Pharmaceuticals, LLC of San Jose, California, completed the first testing stage of the single-vial prototype bioREV technology for use as a vaccine and antibody dehydration method. 

Once we have optimized the formulation and processing parameters for these vaccines we will focus our attention on completing a multi-vial prototype with Starfish Medical of Victoria, BC, for completion in the second quarter of 2009.

> Read more

EnWave is currently developing a third REV technology platform, under the brand name powderREV. This platform will be designed to dehydrate food cultures such as probiotics and enzymes into a bulk powder form that can be added to food and dietary supplements to improve health and nutritional value.

> Read more

Industry News

G. Pascal Gregory’s article in the New York Times contains some key insights into the business opportunities in vaccine development.

“By the mid-1990s innovation in vaccines had virtually come to a halt. But in a stunning reversal, innovators today are chasing dozens of vaccines, stimulated by some recent high-profile successes"

> Read more

EnWave In the News

EnWave was featured in the March 2008 issue of Business in Vancouver. The article, entitled “Richmond blueberry farmer
hopes to hit lucrative dry spell “ focuses on Cal-San Enterprises Ltd. investment of $4.8 million into a plan to tap into a growing North American market demand for exotic dried fruit.

> Read more

> EnWave Homepage
> Latest News
> Investor Information
> Contact Us

> View this email as a web page